In RCC patients, the mPFS was 7.6 months (95 % CI: 3.5–12.9 months) in those who had received prior anti-VEGF therapy (n = 14), which was similar to those who had not (7.2 months [95 % CI: 4.8–14.5], n = 6). Here, VEGFA is linked to renal cell carcinoma.